Last reviewed · How we verify
SPN-810 (18 mg)
SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control.
SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control. Used for Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults.
At a glance
| Generic name | SPN-810 (18 mg) |
|---|---|
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Drug class | 5-HT1A receptor agonist |
| Target | 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
SPN-810 acts as a partial agonist at the 5-HT1A receptor, a serotonin receptor subtype involved in impulse control and behavioral regulation. By enhancing serotonergic signaling through this mechanism, the drug is designed to reduce impulsive behaviors and improve executive function. This mechanism is particularly relevant for conditions characterized by impulsivity and behavioral dyscontrol.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults
Common side effects
- Nausea
- Dizziness
- Headache
- Somnolence
Key clinical trials
- Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD (PHASE2)
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) (PHASE3)
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) (PHASE3)
- Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |